Chemotherapy-induced neuropathy (CIN) symptom persistence among individuals with breast cancer: secondary analysis of recruitment data from an interventional trial
Chemotherapy-induced neuropathy (CIN) affects a large proportion of individuals with breast cancer treated with taxane-based chemotherapy agents (up to 80%); however, questions remain regarding long-term prognosis of this debilitating neurologic complication of breast cancer treatment. We being to assess the scope of the problem by performing a point-prevalence estimate among individuals who developed CIN, assessed at a single (variable) timepoint 3+ months post-treatment completion, within this secondary analysis of recruitment data from a clinical intervention trial (NCT05114005). Per IRB-approved HIPAA waiver for purposes of recruitment screening, we surveyed individuals diagnosed with CIN, who completed treatment at least 3 months prior regarding whether their symptoms had resolved or not. We calculated the proportion of respondents with/without persistent CIN symptoms and performed a sensitivity analysis, computing the largest and smallest possible rate of CIN persistence given the number of non-respondents. Additionally, we analyzed potential predictors of persistent CIN from data available per the HIPAA waiver (e.g., age, time since last taxane dose, HbA1C level) in a complete case analysis. Finally, from a self-identifying subset of individuals with unresolved CIN, we assessed incidence of neuromotor dysfunction using an in-person test of postural control. We surveyed 258 individuals (99.2% female). Mean(SD) age=60.5(11.1); time since last taxane exposure=3.25(2.38) years; HbA1C=5.64(0.61). Symptoms persisted for 84.9% [95% CI 78.6%, 89.9%]. Accounting for both the non-response sensitivity analysis and statistical uncertainty, we estimate bounds of the CIN persistence rate to be no lower than 50.3% and no higher than 93.3%. Higher HbA1C level was associated with symptom persistence ( p =0.037). Variables not associated included total chemotherapy dose ( p =0.8); race (white vs non-white, p =0.4); age ( p =0.09); and time since last taxane dose ( p =0.8). Of those who attended in-person screening, 86.4% demonstrated neuromotor dysfunction. Within this cohort, CIN symptoms were present in 84.9% of individuals who were surveyed a median of 2.77 [95% CI 0.25 to 9.14] years after completion of taxane treatment for breast cancer. More research is needed to improve successful resolution of CIN symptoms and associated neuromotor dysfunction.
Authors
- Bhillie D. Luciani
- Margaret Elena Gatti-Mays (ORCID: https://orcid.org/0000-0001-8914-2897)
- Lise Worthen‐Chaudhari (ORCID: https://orcid.org/0000-0003-1826-0380)
- Sagar D. Sardesai (ORCID: https://orcid.org/0000-0002-2688-0486)
- Patrick Schnell (ORCID: https://orcid.org/0000-0002-2343-208X)
- Maryam B. Lustberg (ORCID: https://orcid.org/0000-0001-8559-5645)
- Ashley Pariser Davenport (ORCID: https://orcid.org/0000-0002-7993-6316)
Institutions
- The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (US)
- Yale University (US)
- The Ohio State University (US)
Publication Details
- Journal
- Breast Cancer Research
- Published
- 2026-11-16
- DOI
- https://doi.org/10.1186/s13058-026-02385-7
- Primary Topic
- Cancer Treatment and Pharmacology
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Institute on Aging